Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Hemophilia Clinical Trials

A listing of Hemophilia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (52) clinical trials

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients Who Have Been Diagnosed With Hemophilia A

The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.

Phase N/A

A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI

As a result of many technological advances in the last two decades, current factor VIII (FVIII) concentrates (both plasma-derived and recombinant products) are considered very safe in terms of pathogen safety. The development of inhibitors against FVIII or factor IX (FIX) is considered as a major complication during replacement therapy …

Phase N/A

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

This observational study consists of a patient and a physician survey. This survey will consist of questions developed by Bayer and submitted to the Steering Committee of the existing registry, ATHN-2. Once enrolled to participate in the ATHN-2 registry and provided consent to participate in the Bayer nested study, patients …

Phase N/A

Drug Use Investigation of Kovaltry in Hemophilia A Patients

This company-sponsored study is a single-arm, prospective, observational study in hemophilia A patients administered Kovaltry. 200 cases will be planned to be registered as safety analysis set in three-year period. Within 200 cases, 50 cases less than 12 years old will be planned to be registered. Target population are all …

Phase N/A

Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins

The investigators propose, as part of the study, to carry out for each patient: An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115, CCR2, CX3CR1, CD163 and CD206). A population assessment of Myeloid-Derived Suppressor Cells (MDSC). Assays of cytokines and chemokines involved in inflammation by multiplex …

Phase N/A

Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT

This pharmacokinetic profile will be obtained in only in patient using Advate (INN-octocog alfa) or Adynovi (INN- rurioctocog alfa pegol), both recombinant intravenous FVIII products, with myPKFiT. This patients will be followed during the period of 12 months, and the pharmacokinetic will be measured collecting at least 2 blood samples, …

Phase N/A

Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions

Currently, the exploration of primary hemostasis (a physiological phenomenon used to stop bleeding) is imperfect because it is based on targeted tests for platelets or von Willebrand factor, without taking into account blood flow and other blood cells (red and white blood cells). Tests for whole blood and flow conditions …

Phase N/A

Pharmacokinetics Pharmacodynamics and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to …

Phase N/A

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

Open label, prospective, non-interventional, single arm study in patients receiving KOVALTRY as prophylaxis therapy.

Phase N/A

Von Willebrand Factor in Pregnancy (VIP) Study

For pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels > 50-100%, specific guidance is lacking for delivery planning for how high a VWF level should be achieved. Specifically, guidance is lacking on whether VWF …

Phase N/A